CD274 and colorectal carcinoma: Data from the Phase 1 MK-4280-001 study showed numerically higher response rates in patients with PD-L1 positive MSS CRC (CR in 2.8% and PR in 8.3% of patients) compared with those with negative PD-L1 status (no CRs, and PR in 2.9% of patients); response by LAG-3 status was not reported [23].